Clinical Trial Detail

NCT ID NCT02362997
Title Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Dana-Farber Cancer Institute
Indications

diffuse large B-cell lymphoma

Hodgkin's lymphoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.